9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy

Immune checkpoint therapy (ICT) provides substantial clinical benefits to cancer patients, but a large proportion of cancers do not respond to ICT. To date, the genomic underpinnings of primary resistance to ICT remain elusive. Here, we performed immunogenomic analysis of data from TCGA and clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Guangchun, Yang, Guoliang, Hao, Dapeng, Lu, Yang, Thein, Kyaw, Simpson, Benjamin S., Chen, Jianfeng, Sun, Ryan, Alhalabi, Omar, Wang, Ruiping, Dang, Minghao, Dai, Enyu, Zhang, Shaojun, Nie, Fengqi, Zhao, Shuangtao, Guo, Charles, Hamza, Ameer, Czerniak, Bogdan, Cheng, Chao, Siefker-Radtke, Arlene, Bhat, Krishna, Futreal, Andrew, Peng, Guang, Wargo, Jennifer, Peng, Weiyi, Kadara, Humam, Ajani, Jaffer, Swanton, Charles, Litchfield, Kevin, Ahnert, Jordi Rodon, Gao, Jianjun, Wang, Linghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460828/
https://www.ncbi.nlm.nih.gov/pubmed/34556668
http://dx.doi.org/10.1038/s41467-021-25894-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460828/
https://www.ncbi.nlm.nih.gov/pubmed/34556668
http://dx.doi.org/10.1038/s41467-021-25894-9

Ejemplares similares